3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
17
Neoplasms
6
Breast Neoplasms
6
Prostatic Neoplasms
4
Fallopian Tube Neoplasms
4
Pancreatic Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Stomach Neoplasms
1
Prostate Adenocarcinoma
1
Pancreatic Adenocarcinoma
1
Osteosarcoma
1
Oligodendroglioma
1
Neuroblastoma
1
Metastatic Castration-sensitive Prostate Cancer
1
Mesothelioma
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Gemcitabine
4
Fluorouracil
4
dehydroftorafur
3
Taxes
3
Oxaliplatin
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
Radiotherapy
2
Leucovorin
2
Irinotecan
2
tocilizumab
1
selicrelumab
1
niraparib
1
indusatumab
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Tiragolumab
1
Surgical Procedures, Operative
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Image-Guided
1
Radiation
1
Pancreatectomy
1
PEGPH20
1
Nivolumab
1
Losartan
1
Ipilimumab
1
Folfox protocol
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Pancreatic Adenocarcinoma
×
niraparib
×
Clear all
NCT03404960
2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2
Completed
104 enrolled
11 charts